Literature DB >> 1445501

Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

R A Behmand1, S I Harik.   

Abstract

Epidemiologic evidence of an inverse relationship between cigarette smoking and Parkinson's disease suggests that a component of cigarette smoke protects against nigrostriatal degeneration. Nicotine, a major component of cigarette smoke, is similar in chemical structure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and is metabolized in part by the same enzymes that detoxify MPTP. We investigated the effect of chronic nicotine on MPTP neurotoxicity in two strains of mice and found that nicotine increases rather than decreases MPTP toxicity. These results are not compatible with the hypothesis that nicotine is that component of cigarette smoke that protects against nigrostriatal degeneration, at least in the MPTP experimental model of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445501     DOI: 10.1111/j.1471-4159.1992.tb09786.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  A highly effective antiparkinsonian drug of a new structural type.

Authors:  T G Tolstikova; A V Pavlova; Ye A Morozova; O V Ardashov; I V Il'ina; K P Volcho; N F Salakhutdinov; G A Tolstikov
Journal:  Dokl Biol Sci       Date:  2011-01-09

2.  The short-term effect of nicotine chewing gum in patients with Parkinson's disease.

Authors:  P Clemens; J A Baron; D Coffey; A Reeves
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

Review 3.  Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease.

Authors:  Maryka Quik; Danhui Zhang; Matthew McGregor; Tanuja Bordia
Journal:  Biochem Pharmacol       Date:  2015-06-18       Impact factor: 5.858

Review 4.  Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.

Authors:  G W Ross; H Petrovitch
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  The protective role of cigarette smoking against Parkinson's disease via moderation of the interaction between iron deposition in the nigrostriatal pathway and clinical symptoms.

Authors:  Quanquan Gu; Xiaocao Liu; Qingze Zeng; Xiaojun Guan; Cheng Zhou; Tao Guo; Baorong Zhang; Minming Zhang
Journal:  Quant Imaging Med Surg       Date:  2022-07

Review 6.  Nicotine and Parkinson's disease: implications for therapy.

Authors:  Maryka Quik; Kathryn O'Leary; Caroline M Tanner
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

Review 7.  Multiple roles for nicotine in Parkinson's disease.

Authors:  Maryka Quik; Luping Z Huang; Neeraja Parameswaran; Tanuja Bordia; Carla Campos; Xiomara A Perez
Journal:  Biochem Pharmacol       Date:  2009-05-09       Impact factor: 5.858

8.  Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase.

Authors:  Kay Castagnoli; Stefanus J Steyn; Geraldine Magnin; Cornelis J Van Der Schyf; Izel Fourie; Ashraf Khalil; Neal Castagnoli
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

9.  Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra.

Authors:  J Andrés Abin-Carriquiry; Ronald McGregor-Armas; Gustavo Costa; Jessika Urbanavicius; Federico Dajas
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

Review 10.  Nicotinic receptors as CNS targets for Parkinson's disease.

Authors:  Maryka Quik; Tanuja Bordia; Kathryn O'Leary
Journal:  Biochem Pharmacol       Date:  2007-06-17       Impact factor: 5.858

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.